Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

Overview of attention for article published in Frontiers in oncology, April 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

So far, Altmetric has seen 12 X posts from 12 X users, with an upper bound of 36,351 followers.

RT @neerajaiims: Toxicities of PD-1/L-1 Abs> rare, can be serious, early recognition is the key @maughanonc @DavidGillMD @HHammersMD https:…

RT @neerajaiims: Toxicities of PD-1/L-1 Abs> rare, can be serious, early recognition is the key @maughanonc @DavidGillMD @HHammersMD https:…

RT @neerajaiims: Toxicities of PD-1/L-1 Abs> rare, can be serious, early recognition is the key @maughanonc @DavidGillMD @HHammersMD https:…

RT @neerajaiims: Toxicities of PD-1/L-1 Abs> rare, can be serious, early recognition is the key @maughanonc @DavidGillMD @HHammersMD https:…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.